Mutations in the PARP1/2/3 downstream partners BRCA1/2 genes have been reported in adult AML, with a frequency around 1.9% in the NGS-PTL AML cohort (BRCA1: 3/162 cases, BRCA2: 4/162 cases) and below 1.0% in the Beat AML study (BRCA1: 1/622 cases; BRCA2: 2/200). The gene discussed is BRCA2; the disease is acute myeloid leukemia.